Yes, but if a partner wants more data, we should produce it in a phase 3 trial and why not have a subset of subjects generate this…. now. I’m really happy to see these outcome measurements maintained, even if we are a durable pain and function drug in 2025.
I understand the costs to monitor/apply for DMOAD and the monitoring required would be financially onerous (unless a partner is sitting and waiting to strike once 2mg dose is approved, trial design is re-worked and adrenal misnomer is addressed.) F@CK knows. As KP said, no one knows (except a few that think they do).
It’s a piece of information I’ve been waiting for. This is a big moment.
I wonder if DMOAD label can be attained in Aussie TGA provisional approval?
I also wonder if a subset of phase 3 stage 2 trial subjects are outcome measured for DMOAD, whether that data can be used for accelerated approval, too.
Donna, no doubt working on all this. She is a gun. What would we do without her?
- Forums
- ASX - By Stock
- PAR
- Where we at?
Where we at?, page-281
-
-
- There are more pages in this discussion • 415 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $101.4M |
Open | High | Low | Value | Volume |
28.5¢ | 29.5¢ | 28.5¢ | $79.93K | 274.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 12951 | 29.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.0¢ | 23984 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2951 | 0.290 |
2 | 101320 | 0.285 |
4 | 66071 | 0.280 |
2 | 95130 | 0.275 |
8 | 103599 | 0.270 |
Price($) | Vol. | No. |
---|---|---|
0.300 | 23984 | 3 |
0.305 | 52600 | 2 |
0.310 | 22870 | 4 |
0.320 | 127570 | 5 |
0.325 | 3435 | 3 |
Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |